LONG MINI-FUTURE - NOVO-NORDISK B | Market Closed - Börse Stuttgart 07:14:04 25/06/2024 BST | ||
| 23.75 EUR | -0.21% |
|
| Current month | +8.85% | ||
| 1 month | +6.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 23.75 | -0.21% |
| 24/06/24 | 23.8 | +0.80% |
| 20/06/24 | 23.61 | +0.34% |
| 19/06/24 | 23.53 | -0.13% |
| 18/06/24 | 23.56 | -1.71% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 07:14 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VN5CHR |
| ISIN | DE000VN5CHR1 |
| Date issued | 07/11/2016 |
| Strike | 98.15 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.36 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.02 € |
|---|---|
| Lowest since issue | 0.22 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,028
DKK
Average target price
938.1
DKK
Spread / Average Target
-8.74%
- Stock Market
- Certificates
- Certificat
